COVID-19 Vaccine AstraZeneca suspension for injection COVID-19 Vaccine (ChAdOx1-S [recombinant]) ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
53シェーグレン症候群1

53. シェーグレン症候群


臨床試験数 : 305 薬物数 : 325 - (DrugBank : 104) / 標的遺伝子数 : 58 - 標的パスウェイ数 : 188
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-001414-10-NL
(EUCTR)
30/03/202124/03/2021Response to corona vaccination in patients with primary Sjögren's syndromeVaccine response against SARS-CoV-2 in patients with primary Sjögren’s syndrome - VaccineSS Primary Sjögren's syndrome;Therapeutic area: Diseases [C] - Immune System Diseases [C20]Trade Name: Comirnaty concentrate for dispersion for injection
Trade Name: COVID-19 Vaccine AstraZeneca suspension for injection COVID-19 Vaccine (ChAdOx1-S [recombinant])
Trade Name: COVID-19 Vaccine Janssen suspension for injection COVID-19 vaccine (Ad26.COV2-S [recombinant])
University Medical Center GroningenNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
180Phase 4Netherlands